临床决策支持联合审计反馈对冠状动脉造影患者急性肾损伤预防的影响:一项随机临床试验
该研究为阶梯整群随机临床试验,在加拿大阿尔伯塔省3个心导管室纳入34名心脏介入医师和7106例接受非急诊冠脉造影/PCI、未透析且预测AKI风险>5%的患者。干预包括教育外展、计算机化临床决策支持(对比剂用量和血流动力学指导的静脉液体目标)及审计反馈。结果显示干预期AKI发生率为7.2%(310/4327),对照期为8.6%(299/3493),组间差异-2.3%(95%CI -0.6%至-4.1%),OR 0.72(95%CI 0.56-0.93),P=0.01。干预还降低了对比剂过量使用比例(38.1% vs 51.7%)和静脉液体不足比例(60.8% vs 75.1%),主要不良心血管事件和肾脏事件无显著差异。
要点
- 在预测AKI风险>5%的冠脉造影/PCI患者中,干预期AKI发生率为7.2%(310/4327),对照期为8.6%(299/3493),OR 0.72(95%CI 0.56-0.93),P=0.01。
- 干预期对比剂过量使用比例降至38.1%,对照期为51.7%,组间差异-12.0%(95%CI -14.4%至-9.4%),OR 0.77(95%CI 0.65-0.90),P=0.002。
- 干预期静脉液体不足比例降至60.8%,对照期为75.1%,组间差异-15.8%(95%CI -19.7%至-12.0%),OR 0.68(95%CI 0.53-0.87),P=0.002。
- 主要不良心血管事件和主要不良肾脏事件在组间无显著差异;12项预设次要结局中有8项无显著差异。
- 作者指出,该干预在研究环境之外是否有效尚需进一步研究。
适用人群与场景
- 纳入标准:年龄≥18岁,接受非急诊冠状动脉造影、经皮冠状动脉介入治疗(PCI)或两者兼有,未接受透析,且预测AKI风险>5%的患者。
- 研究场景:加拿大阿尔伯塔省3个心导管室,介入医师为所有心脏介入医师。
诊断标准与关键阈值
- 纳入标准要求预测AKI风险>5%;原文未给出预测模型的具体评分界值或计算方法。
- 主要结局AKI的定义原文未具体说明诊断标准。
处置流程与药物剂量
- 干预措施包括:对心脏介入医师进行教育外展、提供计算机化临床决策支持(针对对比剂用量和血流动力学指导的静脉液体目标)以及审计与反馈。
- 对照期为常规诊疗,医师不接受干预。
研究设计与关键结果
- 研究设计:阶梯整群随机临床试验,在加拿大阿尔伯塔省3个心导管室进行,2018年1月至2019年9月期间随机分配干预开始日期,随访至2020年11月。
- 样本量:34名心脏介入医师(分为8个集群)实施了7820例手术,涉及7106例符合纳入标准的患者。
- 干预组:31名医师实施了4327例手术(4032例患者;平均年龄70.3岁[SD 10.7],女性1384例[32.0%]);对照组:34名医师实施了3493例手术(3251例患者;平均年龄70.2岁[SD 10.8],女性1151例[33.0%])。
- 主要结局:AKI发生率干预期为7.2%(4327例手术中310例事件),对照期为8.6%(3493例手术中299例事件);组间差异-2.3%(95%CI -0.6%至-4.1%);OR 0.72(95%CI 0.56-0.93);P=0.01。
- 次要结局:对比剂过量使用比例干预期38.1% vs 对照期51.7%,组间差异-12.0%(95%CI -14.4%至-9.4%),OR 0.77(95%CI 0.65-0.90),P=0.002;静脉液体不足比例干预期60.8% vs 对照期75.1%,组间差异-15.8%(95%CI -19.7%至-12.0%),OR 0.68(95%CI 0.53-0.87),P=0.002。
- 12项预设次要结局中有8项无显著差异;主要不良心血管事件和主要不良肾脏事件组间无显著差异。
证据类型、等级与局限
- 证据类型:阶梯整群随机临床试验(RCT)。
- 局限:作者指出,该干预在研究环境之外是否有效尚需进一步研究。
对床旁实践的改变
- 对于预测AKI风险>5%的接受非急诊冠脉造影/PCI的患者,对介入医师实施教育外展、计算机化临床决策支持(对比剂用量和血流动力学指导的静脉液体目标)及审计反馈,可降低AKI发生率(干预期7.2% vs 对照期8.6%,OR 0.72,P=0.01),并减少对比剂过量使用和静脉液体不足。
- 作者认为,该干预在研究环境之外是否有效尚需进一步研究。
指南或共识出处
- 临床试验注册号:ClinicalTrials.gov NCT03453996。
- 原文未引用具体指南或共识。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Contrast-associated acute kidney injury (AKI) is a common complication of coronary angiography and percutaneous coronary intervention (PCI) that has been associated with high costs and adverse long-term outcomes.
OBJECTIVE: To determine whether a multifaceted intervention is effective for the prevention of AKI after coronary angiography or PCI.
DESIGN, SETTING, AND PARTICIPANTS: A stepped-wedge, cluster randomized clinical trial was conducted in Alberta, Canada, that included all invasive cardiologists at 3 cardiac catheterization laboratories who were randomized to various start dates for the intervention between January 2018 and September 2019. Eligible patients were aged 18 years or older who underwent nonemergency coronary angiography, PCI, or both; who were not undergoing dialysis; and who had a predicted AKI risk of greater than 5%. Thirty-four physicians performed 7820 procedures among 7106 patients who met the inclusion criteria. Participant follow-up ended in November 2020.
INTERVENTIONS: During the intervention period, cardiologists received educational outreach, computerized clinical decision support on contrast volume and hemodynamic-guided intravenous fluid targets, and audit and feedback. During the control (preintervention) period, cardiologists provided usual care and did not receive the intervention.
MAIN OUTCOMES AND MEASURES: The primary outcome was AKI. There were 12 secondary outcomes, including contrast volume, intravenous fluid administration, and major adverse cardiovascular and kidney events. The analyses were conducted using time-adjusted models.
RESULTS: Of the 34 participating cardiologists who were divided into 8 clusters by practice group and center, the intervention group included 31 who performed 4327 procedures among 4032 patients (mean age, 70.3 [SD, 10.7] years; 1384 were women [32.0%]) and the control group included 34 who performed 3493 procedures among 3251 patients (mean age, 70.2 [SD, 10.8] years; 1151 were women [33.0%]). The incidence of AKI was 7.2% (310 events after 4327 procedures) during the intervention period and 8.6% (299 events after 3493 procedures) during the control period (between-group difference, -2.3% [95% CI, -0.6% to -4.1%]; odds ratio [OR], 0.72 [95% CI, 0.56 to 0.93]; P = .01). Of 12 prespecified secondary outcomes, 8 showed no significant difference. The proportion of procedures in which excessive contrast volumes were used was reduced to 38.1% during the intervention period from 51.7% during the control period (between-group difference, -12.0% [95% CI, -14.4% to -9.4%]; OR, 0.77 [95% CI, 0.65 to 0.90]; P = .002). The proportion of procedures in eligible patients in whom insufficient intravenous fluid was given was reduced to 60.8% during the intervention period from 75.1% during the control period (between-group difference, -15.8% [95% CI, -19.7% to -12.0%]; OR, 0.68 [95% CI, 0.53 to 0.87]; P = .002). There were no significant between-group differences in major adverse cardiovascular events or major adverse kidney events.
CONCLUSIONS AND RELEVANCE: Among cardiologists randomized to an intervention including clinical decision support with audit and feedback, patients undergoing coronary procedures during the intervention period were less likely to develop AKI compared with those treated during the control period, with a time-adjusted absolute risk reduction of 2.3%. Whether this intervention would show efficacy outside this study setting requires further investigation.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03453996.
参考来源
- James MT, Har BJ, Tyrrell BD, et al. Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial. JAMA. 2022. PMID: 36066520. doi:10.1001/jama.2022.13382
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。